FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2274104882> ?p ?o ?g. }

• W2274104882 abstract "In a single institution, we have used recombinant interferon- (IFN-) to treat 116 newly diagnosed Philadelphia-positive (Ph+) chronic myeloid leukemia (CML) patients and analyzed the predictive factors for response and survival. The patients whose median age was 50.3 years (range, 9 to 70) were administered IFN- (5 million units/m2/d) subcutaneously. The IFN- dose was subsequently adjusted to maintain the white blood cell and platelet counts between 1.5 and 5 × 109/L, 50 and 100 × 109/L, respectively. At diagnosis, the Sokal score was used to classify the patients into three groups: low (n = 57), intermediate (n = 42), and high risk (n = 16). A complete hematological response (CHR) was achieved in 93 cases (80.2%). Of the 116 patients, 113 were available for cytogenetic evaluation. Fifty patients (43%) achieved a major cytogenetic response (MCR) (=65% marrow Ph− cells), 37 of them having a complete cytogenetic response (CCR). The estimated 5-year survival of the 116 patients was 68% ± 11% (95% confidence interval [CI]) with a median follow-up of 42 months (range, 3 to 114) and 85% ± 11% (95% CI) with a median follow-up of 30.9 (range, 3 to 111) when patients were censored at the time of transplantation. Event-free survival at 5 years (adding death and transplant as event) was 46% ± 11% (95% CI). Using proportional hazards regression to study time-dependent variables, we confirmed that the most significant factor associated with survival was the cytogenetic response (MCR or CCR) (P < .0001). This factor was independent compared with the Sokal score and baseline variables used to calculate the Sokal score. Moreover, using either univariate or multivariate analysis, the achievement of CHR within 3 months was strongly correlated with MCR (P < .0001). Minimum cytogenetic response (mCR, ie, at least 5% of Ph− metaphases) at 3 months was also a significant predictive factor for MCR (P < .0001). These results show that IFN- can induce a high rate of hematological and cytogenetic response when administered in doses leading to myelosuppression. Factors such as the achievement of CHR and mCR within 3 months could be useful to identify early those patients who will not respond to IFN- and who need alternative treatments such as stem cell transplantation." @default.
• W2274104882 created "2016-06-24" @default.
• W2274104882 creator A5001073047 @default.
• W2274104882 creator A5003572390 @default.
• W2274104882 creator A5019150082 @default.
• W2274104882 creator A5027305135 @default.
• W2274104882 creator A5028900948 @default.
• W2274104882 creator A5028925493 @default.
• W2274104882 creator A5031019986 @default.
• W2274104882 creator A5035436135 @default.
• W2274104882 creator A5041817169 @default.
• W2274104882 creator A5044166434 @default.
• W2274104882 creator A5058334809 @default.
• W2274104882 creator A5069539777 @default.
• W2274104882 creator A5087328005 @default.
• W2274104882 date "1998-12-01" @default.
• W2274104882 modified "2023-10-17" @default.
• W2274104882 title "Response at Three Months Is a Good Predictive Factor for Newly Diagnosed Chronic Myeloid Leukemia Patients Treated by Recombinant Interferon-" @default.
• W2274104882 cites W1498708301 @default.
• W2274104882 cites W1799579309 @default.
• W2274104882 cites W188630774 @default.
• W2274104882 cites W1928548710 @default.
• W2274104882 cites W2012960044 @default.
• W2274104882 cites W2038990138 @default.
• W2274104882 cites W2039978091 @default.
• W2274104882 cites W2055352087 @default.
• W2274104882 cites W2058190985 @default.
• W2274104882 cites W2076372887 @default.
• W2274104882 cites W2081849198 @default.
• W2274104882 cites W2089483984 @default.
• W2274104882 cites W2094338232 @default.
• W2274104882 cites W2111946771 @default.
• W2274104882 cites W2112085886 @default.
• W2274104882 cites W2127546252 @default.
• W2274104882 cites W2143108209 @default.
• W2274104882 cites W2162258100 @default.
• W2274104882 cites W2337277825 @default.
• W2274104882 cites W2337803710 @default.
• W2274104882 cites W236820854 @default.
• W2274104882 cites W2403285790 @default.
• W2274104882 cites W2438648923 @default.
• W2274104882 cites W2463564403 @default.
• W2274104882 cites W2465903784 @default.
• W2274104882 cites W2508058084 @default.
• W2274104882 cites W2512753555 @default.
• W2274104882 cites W977069352 @default.
• W2274104882 doi "https://doi.org/10.1182/blood.v92.11.4059.423k34_4059_4065" @default.
• W2274104882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9834210" @default.
• W2274104882 hasPublicationYear "1998" @default.
• W2274104882 type Work @default.
• W2274104882 sameAs 2274104882 @default.
• W2274104882 citedByCount "21" @default.
• W2274104882 countsByYear W22741048822013 @default.
• W2274104882 countsByYear W22741048822014 @default.
• W2274104882 countsByYear W22741048822016 @default.
• W2274104882 countsByYear W22741048822017 @default.
• W2274104882 crossrefType "journal-article" @default.
• W2274104882 hasAuthorship W2274104882A5001073047 @default.
• W2274104882 hasAuthorship W2274104882A5003572390 @default.
• W2274104882 hasAuthorship W2274104882A5019150082 @default.
• W2274104882 hasAuthorship W2274104882A5027305135 @default.
• W2274104882 hasAuthorship W2274104882A5028900948 @default.
• W2274104882 hasAuthorship W2274104882A5028925493 @default.
• W2274104882 hasAuthorship W2274104882A5031019986 @default.
• W2274104882 hasAuthorship W2274104882A5035436135 @default.
• W2274104882 hasAuthorship W2274104882A5041817169 @default.
• W2274104882 hasAuthorship W2274104882A5044166434 @default.
• W2274104882 hasAuthorship W2274104882A5058334809 @default.
• W2274104882 hasAuthorship W2274104882A5069539777 @default.
• W2274104882 hasAuthorship W2274104882A5087328005 @default.
• W2274104882 hasConcept C126322002 @default.
• W2274104882 hasConcept C141071460 @default.
• W2274104882 hasConcept C203014093 @default.
• W2274104882 hasConcept C2778461978 @default.
• W2274104882 hasConcept C2778488018 @default.
• W2274104882 hasConcept C2778729363 @default.
• W2274104882 hasConcept C2779282312 @default.
• W2274104882 hasConcept C2911091166 @default.
• W2274104882 hasConcept C44249647 @default.
• W2274104882 hasConcept C50382708 @default.
• W2274104882 hasConcept C71924100 @default.
• W2274104882 hasConcept C90924648 @default.
• W2274104882 hasConceptScore W2274104882C126322002 @default.
• W2274104882 hasConceptScore W2274104882C141071460 @default.
• W2274104882 hasConceptScore W2274104882C203014093 @default.
• W2274104882 hasConceptScore W2274104882C2778461978 @default.
• W2274104882 hasConceptScore W2274104882C2778488018 @default.
• W2274104882 hasConceptScore W2274104882C2778729363 @default.
• W2274104882 hasConceptScore W2274104882C2779282312 @default.
• W2274104882 hasConceptScore W2274104882C2911091166 @default.
• W2274104882 hasConceptScore W2274104882C44249647 @default.
• W2274104882 hasConceptScore W2274104882C50382708 @default.
• W2274104882 hasConceptScore W2274104882C71924100 @default.
• W2274104882 hasConceptScore W2274104882C90924648 @default.
• W2274104882 hasLocation W22741048821 @default.
• W2274104882 hasOpenAccess W2274104882 @default.
• W2274104882 hasPrimaryLocation W22741048821 @default.
• W2274104882 hasRelatedWork W1430390330 @default.
• W2274104882 hasRelatedWork W1498708301 @default.
• W2274104882 hasRelatedWork W1799579309 @default.

• next